Review Article

Regulatory Networks, Management Approaches, and Emerging Treatments of Nonalcoholic Fatty Liver Disease

Bing Yang, Xi Yang, Xumei Tan, Liqing Lu, Wei Fan, Lucia Barbier-Torres, Justin Steggerda, Ting Liu, and Heping Yang

1Department of Geriatric Endocrinology and Metabolism, Guangxi Key Laboratory of Precision Medicine in Cardio-Cerebrovascular Diseases Control and Prevention, Guangxi Clinical Research Center for Cardio-Cerebrovascular Diseases, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
2Department of Gastroenterology and Thoracic Surgery, Key Laboratory of Cancer Proteomics of Chinese Ministry of Health, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China
3Division of Digestive and Liver Diseases, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
4Northwestern Medicine Organ Transplantation Center, Arkes Pavilion, Chicago, IL 60611, USA

Correspondence should be addressed to Xi Yang; yangxi@sr.gxmu.edu.cn and Heping Yang; heping.yang@cshs.org

Received 30 June 2022; Accepted 5 September 2022; Published 8 November 2022

1.Introduction

Nonalcoholic fatty liver disease (NAFLD) refers to hepatic steatosis >5% without excessive drinking, hepatitis, drug use, etc. [1]. NAFLD comprises a continuum of diseases ranging from simple hepatic steatosis to nonalcoholic liver disease (NASH), liver cirrhosis, and HCC [2]. At present, the global prevalence of NAFLD is increasing, posing a serious threat to human life and health, and there is an urgent need for new methods to prevent and treat NAFLD. Metabolic syndrome, which typically includes abdominal obesity, hyperglycemia, dyslipidemia, and systemic hypertension, is the strongest risk factor for NAFL and NASH, and the association is bidirectional [3].

The nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) transcription factor family is composed of five cellular DNA-binding subunits: p50, p52, cRel, p65 (also known as RELA), and RELB, which are encoded by NF-κB1, NF-κB2, REL, RELA, and RELB, respectively. The heterodimer, p50/p65, is the most common form of NF-κB and is a key driver in liver cancer [4]. NF-κB is an important inflammatory mediator, involved in both the inflammatory pathway and lipid metabolism. NF-κB promotes the progression of NAFLD by mediating liver inflammation, immune response, hepatocyte death, and later compensatory proliferation [5]. While basal NF-κB activity in hepatocytes can promote HCC by inducing inflammation, it also can suppress the compensatory proliferation and prevent HCC.
development by inhibiting apoptotic pathways [5,6]. Considering this manner, we can say that NF-κB has a dual function in the progression of NAFLD to HCC.

Recent studies have found that hepatokines, myokines, adipokines, and stellakines are also involved in the regulation of the pathogenesis of NAFLD. The characterization of the crosstalk of NF-κB with these factors will contribute to a better understanding of the molecular mechanisms involved in the progression of NAFLD. In this review, we describe the relationship between NF-κB and hepatokines, stellakines, adipokines, and myokines in hepatic stellate cells (HSCs), adipocytes, hepatocytes, and myocytes, respectively, and their regulatory signaling pathway. We then reviewed recent Wenxian counties to summarize new screening, diagnosis, and referral modalities for NAFLD/NASH, as well as potential therapeutic agents.

2. Hepatokines and NF-κB Activation

As the primary parenchymal cell type in the liver, hepatocytes may suffer injury or death under various pathogenic conditions accompanying metabolic changes, such as obesity, insulin resistance (IR), and diabetes. Under these circumstances, hepatocytes secrete signaling proteins, named hepatokines, which are closely related to lipid metabolism, oxidative stress, IR, inflammation, and other pathophysiological processes [7]. Studies have shown that NF-κB plays an important role in the initiation and development of NAFLD. Knocking down p65 in mice on a high-fat diet (HFD) reduces liver steatosis and IR [8]. IKK-β acts as inhibitor of nuclear factor kappa-B kinase subunit beta. The mouse model of constitutively active IKK-β in hepatocytes leads to activated NF-κB independently of inflammation and promotes liver fat synthesis and cholesterol synthesis [9].

Under normal circumstances, NF-κB is isolated in the cytoplasm bound to the κB inhibitor (IκB) protein, which inhibits its nuclear localization. Site-specific phosphorylation of IκB (α, β, and ε) by IKK-β plays an important role in the activation of NF-κB [10]. In NAFLD, increased adipogenesis and mitochondrial dysfunction lead to oxidative stress, which can inhibit insulin signaling by activating IKK-β and Jun N-terminal kinase (JNK) [11,12]. Hepatokines can also regulate the expression of IKK-β [13]. The latter inhibits insulin signal transduction by phosphorylating insulin receptor substrates 1 and 2 [14]. This suggests that IKK-β deficiency improves glucose tolerance and insulin sensitivity and inhibits the NF-κB pathway to limit adipogenesis and inflammatory processes. Hepatokines, including retinol fibroblast growth factor 21 (FGF21), high-mobility group box 1 (HMGB1), dipeptidyl peptidase 4 (DPP4), binding protein 4 (RBP4), alpha 2-HS glycoprotein (ASHG or FETUA), sex hormone binding globulin (SHBG), leukocyte cell-derived chemotaxin 2 (LECT2), and follistatin (FST), are involved in driving NAFLD by interaction with NF-κB (Figure 1).

2.1. FGF21. FGF21 is an endocrine factor, mainly secreted by hepatocytes, which regulates the metabolism of liver, skeletal muscle, fat, and other organs. Studies have shown that FGF21 deficiency leads to glucose metabolism dysfunction as well as IR in mice, and exogenous FGF21 intake attenuates hepatic steatosis in mice [15]. However, other authors have suggested that serum FGF21 levels are elevated in patients with NAFLD and positively correlate with intrahepatic triglycerides (TG) [16]. “FGF21 resistance” may explain these seemingly opposite findings. β-Klotho is a single-pass transmembrane protein known as a co-receptor for FGF21 and is expressed mainly in liver. It is reported that TNF-α
can inhibit the expression of FGF21 receptor β-klotho [17], which may reduce the response to FGF21 and result in increased pathological compensation to FGF21. In addition, NAFLD-related states such as insulin resistance and oxidative stress may also stimulate FGF21 expression. Farnesoid X (FXR) receptor is a ligand-activated transcription factor that regulates bile acid, glucose, and lipid metabolism. PPARα acts as the master regulator of lipid metabolism. Regulatory properties of FGF21 derive from its intrinsic ability to act as ligand for a range of receptors including nuclear receptors FXR and PPARα [18]. In parallel, FGF21 and NF-κB crosstalk regulate the phenotype of HSCs and the progression toward NASH [19]. TLR4 is a cell surface pattern recognition receptor. IL-17A regulates the activities of NF-κB and mitogen-activated protein kinases. The expression of NF-κB is increased in FGF21 knockdown hepatocytes and promotes the progression of NASH to HCC through the axis of Toll-like receptor 4 (TLR4)/NF-κB/IL-17A axis [20]. FGF21 downregulates IκBα phosphorylation and NF-κB nuclear translocation in HSCs to inhibit their activation, reducing the ratio of Bcl-2 to Bax to promote apoptosis, thereby mitigating the deposition of α-smooth muscle actin (α-SMA) and collagen to reduce fibrosis [19]. In addition, studies have shown that NF-κB negatively regulates FGF21 transcription by directly binding to its promoter DNA, and FGF21 can promote the transition of NAFLD to HCC through the NF-κB pathway [21]. In NASH-HCC models, lack of FGF21 caused significant upregulation of the hepatocyte-derived IL-17A via TLR4 and NF-κB signaling, which suggests that FGF21 and NF-κB may be involved in the transition of NASH-HCC. Therapeutic approaches targeting FGF21 are expected to delay the progression of the disease.

2.2. HMGB1. HMGB1 is a highly conserved, abundant, nonhistone nuclear protein essential for life, which can regulate gene transcription and maintain nucleosome function. In addition, in liver injury such as NAFLD, HMGB1 can also be released by damaged hepatocytes due to excessive lipid accumulation [22]. After its release, HMGB1 binds to the receptor for advanced glycosylation end products as well as TLR receptors, subsequently activating a series of signaling cascades, such as NF-κB and MAPK pathways, which further triggers liver inflammation and promotes the progression of the disease [23]. Studies have shown that HMGB1 is elevated in NAFLD patients and that it accelerates liver damage and inflammation in the early stages of NAFLD [24]. Deletion of HMGB1 in hepatocytes increases early body weight gain and lipid accumulation in mice and increases ER stress in liver and hepatocytes to promote liver injury during NAFLD [25]. Inhibition of HMGB1 release from hepatocytes attenuates liver damage [26]. Further mechanistic studies showed that HMGB1 is mainly involved in the progression of the disease by regulating NAFLD-related inflammation and fatty acid metabolism. We mentioned earlier that extracellular HMGB1 can promote the occurrence of sterile inflammation through NF-κB. IKB-α is one of the binding targets of HMGB1, IKB-α acts as an inhibitor on NF-κB, and deletion of HMGB1 downregulates NF-κB/p65 phosphorylation and expression [27]. Studies have shown that enhancement of NF-κB signaling by HMGB1 promotes NAFLD progression to HCC and regulates cell proliferation, invasion, and metastasis in HCC cell lines [28, 29]. Inhibiting this pathway can reduce oxidative stress in NASH mice and enhance the recruitment of inflammatory factors to alleviate liver injury [30]. Therefore, intrahepatic and extracellular HMGB1 play distinct roles, and blocking the HMGB1-NF-κB axis and HMGB1 translocation may serve as a potential therapeutic target for reducing inflammation and NAFLD.

2.3. DPP4. DPP4 is involved in the pathological process of various chronic liver diseases, such as NAFLD, liver fibrosis, and liver cancer [31–33]. DPP4 is a ubiquitously expressed transmembrane protein that reduces the expression level of glucagon-like peptide 1 and regulates NAFLD through autocrine and paracrine effects on hepatic insulin signaling [34]. Soluble DPP4 activates MAPK and NF-κB signaling cascades, enhances inflammatory responses in diseases, and exhibits strong pro-fibrotic functions in kidney-, lung-, and liver-related diseases. Based on this, DPP4 inhibitors, such as sitagliptin and alogliptin, which have been widely used in the treatment of T2DM, are being explored in liver disease. The nuclear factor erythroid 2–related factor 2 (Nrf2) is a major regulator of antioxidant and cellular protective genes [35]. Sitagliptin can directly inhibit the proliferation of activated HSCs and protect the liver by promoting Nrf2 and inhibiting NF-κB pathway, reducing the levels of inflammatory factors such as TNF-α and pro-fibrotic factors such as TGF-β [36]. On the other hand, an ameliorative action of sitagliptin in NAFLD was demonstrated via decreasing HMGB1-mediated TLR4/NF-κB signaling, which suppressed inflammation and reduced IR [31]. Alogliptin treatment can also inhibit the activation of HSCs and the deposition of α-smooth muscle actin (α-SMA) and extracellular matrix (ECM), alleviating NASH-related fibrogenesis [37]. Therefore, DDP4 is a potential target for the treatment of NAFLD and NAFLD-related liver fibrosis.

2.4. RBP4. Retinol binding protein 4 (RBP4) is both a hepatokine and an adipokine. Adipocyte-specific release of human RBP4 has been reported to promote hepatic steatosis [38]. A longitudinal study suggested that RBP4 levels are associated with the development and regression of NAFLD and that they are also an independent predictor of NAFLD progression [39]. It was shown that phosphorylation of RBP4 at Ser536 resulted in a marked increase in the activation of the NF-κB subunit p65 [40]. In this work, it was also found that retinol-bound RBP4 significantly increased the nuclear content of the NF-κB subunit p65 protein and its DNA-binding activity [40]. Both in human retinal capillary endothelial cells and human umbilical vein endothelial cells (HUVEC), RBP4-induced activation of NF-κB and NADPH oxidase stimulates pro-inflammatory proteins expression, thereby inducing endothelial inflammation [40]. Furthermore, RBP4 could exert pro-inflammatory effects by
activating TLR4 and c-JNK signaling in macrophages [41,42]. Studies have demonstrated that TLR4 is expressed in endothelial cells, and activation of downstream NF-κB signaling through TLR4 signaling may become a reality [41, 42]. These results suggest that RBP4 may mediate NF-κB-dependent inflammation by activating TLR4 signaling which may influence NAFLD disease progression.

2.5. FST. FST is a glycosylated plasma protein and a natural antagonist of activin A, which binds and inactivates members of the TGF-β family [43]. Five follistatin-like proteins have now been identified: FST-like 1 (FSTL1), IGFBP7 (FSTL2), FSTL3, FSTL4, and FSTL5. FSTL1 induces gene expression of various NF-κB-related cytokines and chemokines and regulates NF-κB signaling pathway expression, such as IL-1β, TNF-α, IL-6, CXCL8/IL-8, and CCL-2/monocytes and MCP-1 in macrophages [44]. FSTL1 can also induce pro-inflammatory responses by signaling IKKβ-NF-κB [45]. The sensor component of the NLR family pyrin domain containing 3 (NLRP3) inflammasome plays a crucial role in innate immunity and inflammation. Chen and Liu [46] also found that downregulation of FSTL-1 inhibits NLRP3 and TLR4/NF-κB signaling pathways to reduce inflammatory damage during streptococcus pneumoniae infection. FSTL can modulate NF-κB involved in inflammatory processes in reepithelialization, osteoarthritis, chondrocyte expression, and promotion of osteoclast formation in diabetic wound healing. FSTL1 stimulation can activate the phosphorylation of p65 [47]. The FSTL3 promoter contains an element of NF-κB, which in turn stimulates FSTL3 expression [48]. Studies show that the levels of FST increased in NAFLD models, correlating with enhanced levels of collagen and TGF-β1, induced mitochondrial beta-oxidation, and downregulated fatty acid synthase activity [49]. FST is associated with adipose tissue IR and related features, and FST attenuates insulin-mediated suppression of lipolysis in adipocytes, thereby promoting NAFLD [50].

2.6. SHBG. SHBG (a homodimeric glycoprotein produced by hepatocytes) is closely related to metabolic abnormalities [51]. Both in vivo and in vitro experiments demonstrated that serum SHBG levels are reduced in NAFLD and that accumulation of hepatic fat rather than whole body fat is the determinant of decreased circulating SHBG expression [52]. Decreased SHBG may also be secondary to inflammatory factors, as increased TNF-α in response to JNK and NF-κB activation reduces SHBG production [53]. It remains unclear that NF-κB regulates the expression of human SHBG by altering its promoter activity [53]. SHBG plasma levels regulate hepatic lipogenesis via PPARα and are involved in IR in NAFLD patients [54]. SHBG is reduced in T2DM and is closely associated with the risk of NAFLD in patients with diabetes or polycystic ovary syndrome [55]. This shows that SHBG can be used as an important indicator for NAFLD. In addition, SHBG inhibits NAFLD-related hepatocarcinogenesis in postmenopausal women [56]. The above findings suggest that the role of SHBG in NAFLD-HCC may be related to the expression of steroid hormones, which complicates the interpretation of changes in SHBG levels and requires further exploration.

2.7. AHSG. Alpha 2-Heremans-Schmid glycoprotein (AHSG, also known as fetuin-A) is a hepatokine with a multifunctional glycoprotein structure [57]. Cumulative evidence points to a significant association between fetuin-A and NAFLD progression. AHSG is positively correlated with hepatic steatosis and is elevated in NAFLD. Furthermore, it can trigger IR in target tissues such as liver and skeletal muscle [58], and insulin sensitivity is significantly enhanced in AHSG-knockout mice [59]. AHSG is an endogenous inhibitor of tyrosine kinase that abrogates insulin downstream signaling, and serum-purified human AHSG has also been shown to significantly disrupt insulin-stimulated phosphorylation of IR and IRS-1 [60]. Meanwhile, earlier work also found that AHSG acts as an endogenous ligand for TLR4, which not only promotes lipid-induced IR, but also mediates the activation of TLR4 and NF-κB pathways leading to an inflammatory cascade [61]. Reduction of AHSG/TLR4/JNK/NF-κB pathway activation exerts a protective effect against inflammation and obesity as well as liver-related insulin resistance [62]. Some studies have shown that NF-κB can regulate AHSG promoter activity [63]. Fatty acids significantly enhanced the expression of AHSG in the HepG2 by increasing the binding of NF-κB to its promoter. Therefore, focusing on the crosstalk between NF-κB and AHSG could be helpful in treating NAFLD.

2.8. LECT2. LECT2 is an obesity-related hepatokine. Clinical studies have shown that serum LECT2 expression is elevated in NAFLD patients. In vitro studies showed that inhibition of hepatic LECT2 expression in mice attenuated HFD-induced hepatic steatosis, whereas hepatic overexpression of LECT2 aggravated HFD-induced hepatic steatosis and inflammation [64]. LECT2 is positively correlated with inflammation and steatosis, and the increase of LECT2 converts residual hepatic macrophages into M1-like phenotypes and promotes the development of hepatic inflammation [65]. Shen et al. [66] found that LECT2 treatment upregulated the NF-κB-binding activity and nuclear translocation of p65. They also found that Raf-1 in macrophages mediates LECT2 activation of NF-κB, and LECT2-specific changes are responsive to Raf-1 phosphorylation [66]. Sterol-regulatory element binding protein-1c (SREBP-1c) is a novel insulin/JNK2-regulated gene, and the JNK2/ SREBP-1c pathway mediates insulin-induced fatty acid synthesis. In addition, LECT2 can promote cellular lipid accumulation by promoting inflammatory markers through IκB and NF-κB phosphorylation and IL-6 expression, as well as by SREBP-1c-mediated signaling [67]. Thus, LECT2 promotes the development of NAFLD.

3. Stellakines and NF-κB Activation

HSC activation is an important link in the progression of chronic liver diseases to liver cirrhosis and even liver cancer. Activated HSCs secrete numerous pro-inflammatory factors
and produce ECM components such as α-SMA and type I and type III collagen fibers, which drive liver inflammation and mediate hepatocyte death, thus promoting the development of liver disease [68]. Xiong et al. [69] found that activated HSCs in NASH mouse model not only produce ECM components, but also secrete multidistinct signal protein molecules, called “stellakines,” such as amyloid precursor protein (APP), CC chemokines (such as CCL2, CCL11), macrophage-colony stimulating factor (M-CSF, also known as CSF1), connective tissue growth factor (CTGF, also called CCN2), and CXC chemokines (such as CXCL1, CXCL10) (Figure 2).

3.1. CSF1 and POSTN. CSF1 is a myeloid cytokine released during infection and inflammation, which has also been shown to regulate the differentiation, proliferation, survival, and activation of monocytes and macrophages [70]. Mohallem and Aryal [71] have demonstrated that CSF1 is highly upregulated in TNFα-treated cells, suggesting that upregulation of CSF1 may activate pro-inflammatory responses and leukocyte invasion of adipose tissue through noncanonical activation of NF-κB signaling mediated by the TNF receptor. The noncanonical NF-κB, the p52-RelB dimer, is thought to respond to selective receptor signals that mediate adaptive immune functions. NIK (NF-κB-inducing kinase) is a central component in the noncanonical NF-κB signaling pathway [72]. Studies have also shown that the CSF1 receptor (CSF1R) also promotes the induction of noncanonical NF-κB signaling during macrophage differentiation [73], which may have the potential to contribute to hepatic repair in fibrotic livers, as macrophage accumulation and phagocytic activity contribute significantly to this process [74]. POSTN (another stellakine) is mainly derived from activated HSCs, and its main function is regulating cell adhesion, proliferation, migration, and apoptosis [75, 76]. POSTN expression can be induced by NF-κB and other pro-inflammatory transcription factors in vitro [77]. However, POSTN cooperates with TNF-α or IL-1α to activate NF-κB in fibroblasts and then induces the expression of CCL2/MCP1, CCL4/MCP1, CCL7/MCP3, CXCL1/KC, CXCL2/MIP-1α, and IL-1β [78]. These results show that interaction between POSTN and NF-κB activation may be a key factor in regulating the inflammatorypathogen link of NAFLD.

3.2. NTNI, GAS6, and WNT4. Ntnrin-1 (NTN1) is included in a family of laminin-related secreted proteins. NTN1 regulates the activation of NF-κB through the uncoordinated-phenotype-5A (also called UNCSA, a NTN1 receptor), because not only does the activation of UNCSA significantly activate the phosphorylation of NF-κB/p65 at Ser536, but the UNCSA upregulates the expression of c-MYC (the NF-κB downstream target) by activating NF-κB to promote cell proliferation [79]. The RAC1 gene is involved in cellular growth and cell-cycle regulation. KCNQ1 opposite strand/antisense transcript 1 (KCNQ1OT1) is a long noncoding RNA gene. Interference or inhibition of NTN1-NF-κB further inhibits c-MYC and leads to downregulation of the expression of RAC1 and inhibition of the hedgehog pathway via downregulation of KCNQ1OT1, ultimately inhibiting HSCs proliferation and epithelial-mesenchymal transition (EMT) in liver fibrosis [80].

Growth arrest-specific 6 (GAS6) is thought to be involved in the stimulation of cell proliferation. GAS6 inhibits NF-κB phosphorylation, chemotaxis, and adhesion affinity between monocytes and endothelial cells [81]. GAS6 prevents activation of TNF receptor associated factor 6 (TRAF6) and NF-κB by upregulating suppressor of cytokine signaling 3 (SOCS3) in cellular models [82]. AS6-AS2 is an identified cancer-related IncRNA. TLR ligands reduce GAS6 by downregulating GAS6-AS2 expression via NF-κB activation, suggesting a bidirectional feedback system between GAS6 and inflammation [81]. WNT4 inhibits NF-κB by noncanonical WNT signaling [83]. WNT4 also activates β-catenin/NF-κB by the cooperation of frizzled 4 and low-density lipoprotein receptor-related protein 6 (LRP6) signaling [84]. Recombinant WNT4 proteins potently inhibit the apical step of transforming growth factor beta-activated kinase 1 phosphorylation, as well as the subsequent steps of RANKL (RANKL induces each critical step in NF-κB activation) -induced p65 phosphorylation and IκBα phosphorylation and degradation [83,85]. Furthermore, WNT4 also inhibits NF-κB-dependent transcription [83]. These facts further demonstrate that several genes interact with NF-κB to regulate the development and progression of NAFLD.

3.3. CXCL1, CXCR4/7, CXCL12, and CXCL16. CXC chemokines are a chemokine subfamily with a CXC motif at the N-terminus, also known as α-chemokines. 17 CXC chemokines have been reported (such as CXCL1, CXCL10, CXCL12, CXCL14, and CXCL16). CXC chemokines affect tumorigenesis on cell recruitment, aggregation migration, invasion, angiogenesis, angiostasis, and lymphangiogenesis [86]. CXCL1 has an additional ELR motif, and VEGF activity induces increased expression of CXCL1 in endothelial cells, which induces angiogenesis through CXCR2 (receptor of CXCL1) [87, 88]. Activation of HIF-1 and NF-κB increases CXCR2 expression in cancer cells during chronic hypoxia [89]. In HUVECs, NF-κB/p65 increases the expression of long intergenic non-protein-coding RNA 1693 (LINC01693, which functions as a miRNA-302d sponge) to enhance CXCL12 expression [90]. miRNA-302d decreases the expression of CXCL12, which shows that hypoxia increases the expression of CXCL12 through NF-κB [86]. Mallory–Denk bodies formed in human alcoholic hepatitis and NASH can mediate TLR3/4 signaling through the NF-κB-CXCR4/7 pathway [91]. LPS and NF-κB activation increase the expression of CXCL16 in HUVEC [92]. Silencing of CXCL16 expression decreases tumor cell migration and cell proliferation via the reduction of NF-κB activation [93].

3.4. CCL11, CCL2, CXCL10, and CTGF. CC chemokines are a subfamily of 27 chemokines that are involved in intercellular communication and can also regulate the microenvironment in some tumors [94]. Activation of ERK MAPK by CCL11 mediates apoptosis resistance in cancer
CCL11-CCL3 interaction activates phosphatidylinositol 3-OH kinase/serine-threonine kinase (PI3K/Akt) signaling pathway in endothelial cells to induce angiogenesis [96]. Furthermore, activation of the CCR3 receptor by CCL11 increases the expression of VEGF in HCC, thereby indirectly promoting angiogenesis [97]. It has been reported that macrophages with NF-kB-mediated mixed canonical and STAT-6-mediated alternating activation phenotypes can produce CCL11 [98]. This makes us think that NF-kB regulation and activation of CCL11 can promote cancer angiogenesis and affect the prognosis of HCC. p50 can inhibit liver inflammation and immune response by regulating CCL2 and CXCL10 secretion by HSCs, alleviating liver injury [99]. p65 inhibits the activation of HSCs and reduces the secretion of stellakines to improve the inflammatory response [100]. Tumor cell-derived CTGF transmits growth-promoting signals to HCC cells by activating nearby HSCs, so CTGF has also been identified as a cornerstone in the HCC microenvironment, but anti-CTGF antibodies are susceptible to inhibiting this interaction [101]. CTGF promotes the nuclear accumulation of p50 and p65 to protect the survival of the primary HSCs. Chaqour et al. [102] demonstrated that NF-kB binds to the binding site in the promoter region of CTGF. Intracellular translocation of NF-kB via the Smad-independent pathway can regulate CTGF expression, whereas TGF-β-induced CTGF expression is inhibited by Bay 11-7082 (NF-kB inhibitor) [103].

4. Adipokines and NF-kB Activation

Adipose tissue (both subcutaneous and visceral) is a fundamental player in systemic inflammatory processes associated with obesity. The involvement of adipose tissue in communication between metabolically active organs requires mediators such as cytokines and adipokines [104]. Adipokines are involved in the regulation of appetite and satiety (e.g., leptin), fat distribution, insulin secretion and sensitivity (e.g., leptin and adiponectin (ADIPOQ)), glucose metabolism (e.g., leptin, adiponectin), adipogenesis, and lipid metabolism and also in the accumulation of endothelial dysfunction and inflammation in the liver (e.g., TNF-α) [105,106]. This implicates that adipokines as important factors in regulating human metabolic diseases such as obesity and NAFLD. Several important adipokines such as leptin, ADIPOQ, RETN, and nicotinamide phosphoribosyl transferase (NAMPT) are closely related to NF-kB (Figure 3).

4.1. RETN. Resistin (RETN) is co-secreted with adiponectin in white mouse adipocytes. NF-kB plays an important role in resistin (RETN) -induced bone remodeling, hyperglycemia-induced increase in RETN expression [107], in vivo development of IR, stimulation of pro-inflammatory cytokines in macrophages and peripheral blood mononuclear cells, and
endothelial dysfunction. A study showed that NF-κB can regulate gene expression of inflammatory responses, cytokines [108], and related oxidative-responsive adipokines such as TNF-α [109].

Kumar et al. [110] demonstrated that two closely linked SNPs underlie the genetic regulation of RETN expression in human monocytes, as they control NF-κB1-p50/p50-homodimer binding, histone acetylation, and C-methylation of the RETN promoter. Regarding RETN’s role in inflammatory responses, it upregulates the expression of monocyte chemoattractant protein 1 (MCP-1) and the release of vascular cell adhesion molecule 1 and intracellular adhesion molecule 1 (ICAM-1) and activates NF-κB in endothelial cells [111,112]. RETN-stimulated phosphorylation and subsequent activation of the signaling proteins p38, JNK, and ERK constitute another mechanism for pro-inflammatory cytokine production [113]. Inhibition of the NF-κB transcription factor may limit the effect of adipokines on joint injury, as visfatin and RETN activate NF-κB signaling through phosphorylation of the ERK/p38/MAPK pathway that induces pro-inflammatory and OA-degrading processes [114]. RETN originally described as an adipocyte-specific hormone is an important link between obesity, insulin resistance, and diabetes. RETN may also act by regulating the canonical NF-κB pathway [115]. Another study also confirmed that human RETN increased p65 expression in a dose-dependent manner, thereby promoting keratin 8 transcriptional expression to inhibit glycogen accumulation in HepG2 cells [116]. Finally, RETN was found to have a pro-inflammatory role in HSCs, suggesting that RETN is involved in liver fibrosis [117]; the serum levels of RETN were higher in NAFLD and were positively correlated with liver inflammation [118].

4.2. LEP. Leptin (LEP), a 16-kDa protein containing 167 amino acids and discovered in 1994, is secreted from adipocytes. LEP is mainly involved in metabolic regulation through three signaling pathways: the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway, PI3K/AKT pathway, and extracellular signal-regulated kinase (ERK) pathway [119].

It was found that NF-κB activation in osteoarthritis (OA) patients upregulates two factors (LEP and its receptor Ob-R) produced by articular cartilage [120]. Chen et al. suggested that LEP could accelerate the expression of NF-κB/p65(RELA), and the crosstalk between the NF-κB signaling pathway and the JAK/STAT signaling pathway could increase the secretion of pro-inflammatory cytokines (e.g., human granulocyte macrophage-colony stimulating factor, IL-1α, and IL-6) [121]. Faustmann et al. [122] found that NF-κB/p65 activation was inversely correlated with LEP.
concentrations. Moreover, RNA-seq analysis by Reilly et al. [123] found that NF-κB1 deficiency could abundantly regulate the expression of inflammatory effectors, antigen presentation, and immune checkpoints through JAK-STAT signaling. Recent studies have shown that inhibition of microglia can reduce food intake, reduce diet-induced obesity, and improve LEP signaling by an NF-κB-dependent approach [124]. Rian, a small RNA, could regulate numerous target genes, and the human homologs of some of these microRNAs have been proposed to both stimulate and inhibit tumorigenesis in other types of malignancies. Rian/miR-210-3p/NF-κB1 (the target of miR-210-3p) feedback loop inactivates the PI3K/Akt pathway [125], suggesting a direct link between NF-κB1 and PI3K/Akt pathway. In general, the role of LEP and NF-κB is reciprocal; LEP can directly activate NF-κB signaling, while NF-κB can indirectly regulate LEP through JAK-STAT, PI3K/AKT, and ERK signaling pathways. LEP may regulate pyroptotic-like death of macrophages and hepatocytes in NAFLD progression via CDB8+ T lymphocytes [126]. Taken together, LEP and NF-κB may communicate as promising candidates for the treatment of inflammatory and metabolic diseases.

4.3. ADIPOQ. Adiponectin, also known as ADIPOQ, discovered in 1995, is a 30-kDa protein consisting of 244 amino acids, which mainly signals on target cells through two adiponectin receptors, ADIPOQ receptor 1 (AdipoR1) and AdipoR2 [127]. Binding of adiponectin to AdipoR1 and R2 activates the phosphorylation of AMPK (downstream mediator of ADIPOQ) and p38 MAPK, as well as increasing PPARα ligand activity [128]. The main physiological function of ADIPOQ is to increase insulin sensitivity, promoting anti-inflammatory and anti-oxidative effects (switching the macrophage phenotype to an anti-inflammatory state reduces inflammatory initiation by reducing Toll-like expression receptor 4), enhancing insulin secretion and vasculoprotective and anti-atherosclerotic effects, and regulating food intake and energy expenditure [128].

ADIPOQ effect on NF-κB activation is bidirectional in different monocyte cell lines, both stimulating and inhibiting it [129]. It was previously reported that ADIPOQ increases NF-κB p65 and enhances the production of pro-inflammatory factor IL-6 through the AdipoR1-AMPK-p38-NF-κB pathways in human synovial fibroblasts [130]. Furthermore, ADIPOQ inhibits NF-κB activation and suppresses inflammation by regulating AMPK [131], which is supported by the finding that ADIPOQ inhibits microglial inflammatory response to amyloid-β oligomer through AdipoR1-AMPK-NF-κB signaling [130]. Yang et al. [132] show that ADIPOQ exerts anti-inflammatory and anti-oxidative stress effects through the neurotin (NNAT)/NF-κB pathway in adipocytes. ADIPOQ can also protect skeletal muscle by reducing the activity of NF-κB in muscle inflammation and myogenesis [133]. Furthermore, ADIPOQ proved to be a biomarker of NAFLD progression to steatohepatitis [134].

4.4. NAMPT. Nicotinamide phosphoribosyltransferase (NAMPT) is associated with aging and diabetes. NAMPT modulates cellular metabolism by affecting the activity of nicotinamide adenine dinucleotide (NAD)-dependent enzymes through the biosynthetic activity of NAD, an essential coenzyme involved in cellular redox reactions and a substrate for NAD-dependent enzymes [135]. In addition to its biological enzymatic functions, NAMPT can also affect a variety of physiological processes and participate in metabolic regulation. Glucose and oxidized low-density lipoprotein activate the PI3K/AKT pathway to stimulate NAMPT protein expression and release in human adipocytes [136]. In vitro studies have shown that NAMPT is stimulated by IR-inducing factors (IL-6 and TNF-α) [137] and that its mRNA expression is increased during adipogenesis. These facts suggest that NAMPT can affect glucose metabolism, IR, and lipogenesis. Several studies have reported that extracellular NAMPT exerts pro-inflammatory effects through induction of iNOS, activation of ERK1/2 [138] and NF-κB [139,140], and cytokine production [140].

Activation of PPARαs downregulates NAMPT expression in the liver of NAFLD patients [141]. In contrast, NAMPT has an antiapoptotic effect in NAFLD, as apoptosis in stress-exposed rat hepatocytes can be ameliorated by its overexpression [141]. NAMPT regulates pro-inflammatory cytokine production and inhibits insulin signaling resistance through JAK2/STAT3 and IKK/NF-κB signaling in HepG2 cells [142]. Furthermore, NAMPT induces NF-κB and MAP kinase (MKK) 3/6-p38 signaling to increase CC chemokine ligand 20 (also called CCL20, an important cytokine for inflammation and fibrosis in the liver) expression in macrophages, which suggests that NAMPT can promote the activation of fibrotic markers in HSCs [143], which may be an important therapeutic target for the treatment of NAFLD.

Taken together, the findings suggest that adipokines regulate the processes involved in the pathogenesis of NAFLD by regulation of oxidative stress, apoptosis, lipid and glucose metabolism, inflammation, and IR [135]. The adipokines-NF-κB network seems to be mainly involved in the inflammatory and fibrosis processes in NAFLD, and whether it is involved in other physiological processes needs further study. Moreover, adipokines have negative effects on NAFLD or NASH, such as (1) activation of HSCs (ADIPOQ, LEP, and RETN); (2) recruitment of macrophages (ADIPOQ and NAMPT); and (3) activation of monocytes (ADIPOQ and RARRES2).

5. Myokines and NF-κB Activation

Actin is a cytokine or peptide produced by skeletal muscle cells and released into the circulation, acting on other cells, tissues, or organs through autocrine, paracrine, or endocrine effects [144,145]. There are many types of myokines, but only 650 myokines have been confirmed so far. Myokines primarily mediate intramuscular signaling and muscle-organ crosstalk with the brain, liver, adipose tissue, gut, pancreas, bone, vascular bed, and skin during exercise [146,147]. IPA assay showed that interleukin-6 (IL-6), interleukin-15 (IL-15), FGF21 (described in 1.1), and brain-derived neurotrophic factor (BDNF) are involved in the development of NAFLD through NF-κB (Figure 4).
5.1. IL-6. Multiple cell types, including leukocytes, adipocytes, and myocytes, are known to secrete IL-6 [148]. IL-6 is associated with chronic inflammation in diseases such as obesity and T2DM [146]. IL-6 promotes insulin-stimulated glucose uptake, lipolysis, and fat oxidation [149]. NAFLD is associated with the elevation of IL-6 [150]. Increased concentrations of soluble IL-6 receptor α (sIL-6Rα) and gp130/sIL-6Rβ (both in the IL-6 cytokine family) prevent NAFLD progression in obese patients [151]. Steatosis leads to upstream activation of IKK-β (inhibitor of NF-κB) to increase signaling of the transcription factor NF-κB, which induces pro-inflammatory mediators such as TNF-α, IL-6 [152], and IL-1β production. These cytokines could recruit and activate the Kupffer cells [153] to mediate inflammation in NASH [154], RELB [155], NF-κB/p65 [156], and NF-κB2 [157]. In conclusion, it is feasible that NF-κB can affect NAFLD and its related complications by regulating IL-6 to regulate inflammation, lipid metabolism, fatty acid oxidation, and insulin sensitivity.

5.2. IL-15. IL-15 is a member of IL-2 superfamily, and its main function is to regulate anabolism in skeletal muscle. It can also mediate exercise-induced muscle-fat crosstalk [158], as it downregulates lipid accumulation in preadipocytes, reduces white adipose tissue (WAT) mass by stimulating adiponectin secretion, and counteracts the effect of TNF-α on muscle protein degradation [159]. In addition, IL-15 treatment prevents HFD-stimulated fatty liver [160], which has the potential to delay the progression of NAFLD. Decreased hepatic resident memory CD8+ T (CD8+ Trm) cells maintained by IL-15 in tissues delayed fibrosis regression, and adoptive transfer of these cells protected mice from fibrotic progression [161]. Furthermore, IL-15 mediates HFD-induced lipid accumulation and inflammation promoting NAFLD [162]. NF-κB is a major mediator of IL-15 signaling in brain endothelial cells, through which IL-15 affects cellular permeability, endocytosis, and intracellular trafficking at the blood-brain barrier level, and it also induces phosphorylation of p65 and nuclear translocation [163]. p50 deficiency may accelerate NASH progression to fibrosis by promoting IL-15 activation to stimulate natural killer T (NKT) cell recruitment [164].

5.3. BDNF. BDNF is a member of the neurotrophic family that is widely expressed in the adult brain and is mainly involved in immune-inflammatory responses [165]. NK-κB can regulate BDNF promoter activity [165]. Xu et al. [165] found that BDNF expression appears to require activity of the MyD88/NF-κB signaling pathway to induce innate immune responses which also induces innate immune responses [165]. BDNF is an important marker for preventing and treating NAFLD [166], as its serum level has positive association with NAFLD [167]. However, no in vitro or in vivo experiments have found the signaling pathway between BNDF and NAFLD.
5.4. New Management Measures for NAFLD and NASH. Different region- and country-specific factors influence the epidemiological incidence of NAFLD. Experts provide new insights into NAFLD disease burden, screening, diagnosis and referral patterns, and available treatment options for NAFLD and NASH in the Middle East [168]. The prevalence of obesity, MetS, and T2DM is increasing simultaneously, and the high prevalence of these NAFLD risk factors increases the disease burden of NAFLD. Given the high prevalence of NAFLD in high-risk populations, most international guidelines recommend routine liver enzyme screening, ultrasonography, and transient elastography for these patients [169,170]. The American Association for the Study of Liver Diseases (AASLD) guidelines currently do not recommend routine screening for NAFLD because of uncertainty about the performance characteristics of diagnostic tests and available treatment options, and they recommend routine screening for NAFLD patients suspected of having diabetes [1]. In contrast, European guidelines recommend screening for NAFLD in all patients with steatosis with persistent abnormalities in liver enzymes [170]. Noninvasive diagnostic methods including serum biomarkers, routine radiology (e.g., ultrasound), computed tomography, magnetic resonance imaging, and assessment of liver stiffness using transient elastography (FibroScan®) and magnetic resonance elastography may be useful for NAFLD/NASH. Diagnosis plays a supporting role [171]. Liver biopsy is considered the gold standard for NASH and fibrosis staging [172]. If a patient is suspected of having NASH tendencies during clinical diagnosis and treatment, timely referral and multidisciplinary team management should be performed. Sanai et al. [168] performed noninvasive examinations and fibrosis scores in NAFLD patients with elevated liver enzymes and radiographic steatosis, respectively. They classified the examination results into low-risk, intermediate-risk, and high-risk. Diet and exercise therapy for patients with low-risk scores, liver biopsy for patients with intermediate scores, and dietary therapy for patients with NAFLD with high-risk scores when laboratory therapy is not appropriate. However, an effective diagnosis of NAFLD is currently lacking [173], and effective multidisciplinary collaboration across healthcare fields would be beneficial to improve the understanding of NAFLD and NASH.

6. Mechanism of Action and Therapeutic Benefits of Silymarin

Silymarin is a lipophilic extract that can be extracted from the dried seeds and fruits of the milk thistle plant (S. marianum). Johannes Gottfried Rademacher first discovered in the 19th century that an extract or “tincture” of milk thistle seeds was beneficial in treating patients with liver disease [174,175]. Silymarin (milk thistle extract) is a complex mixture of compounds of plant origin, mainly identified as flavonoid lignans, flavonoids (taxifolin, quer cetin), and polyphenolic molecules [176]. The four major flavonolignan isomers in silymarin are silybin, isosilybin, silymarin, and silybin. Silymarin has antioxidant properties, anti-inflammatory properties, anti-fibrotic effects, and insulin resistance modulation.

German scientists at the University of Munich first isolated silymarin in 1968, and then it was described and patented by Madaus (German herbal medicine manufacturer) as a specific treatment “for liver diseases” [175]. Rottapharm/Madaus (Cologne, Germany) developed the first commercial silymarin formulation which meets the analytical specifications reported in European Pharmacopoeia 01/2005 “Milk Thistle Fruit” [177]. In 2000, the National Center for Complementary and Alternative Medicine (NCCAM) published a review indicating that the clinical efficacy of milk thistle has not been established, despite evidence of silymarin in various liver conditions [178]. From November 2012 to August 2014, at a tertiary hospital in Kuala Lumpur, Malaysia, patients were randomly assigned to receive silymarin (700 mg; n = 49 patients) or placebo (n = 50 patients) three times a day for 48 weeks [179]. The results showed that the percentage of patients achieving the primary efficacy outcome did not differ significantly between the groups (32.7% in the silymarin group and 26.0% in the placebo group; P = 0.467) [179]. However, patients in the silymarin group had less fibrosis, liver stiffness measurements (30% or more; 24.2%), mean aspartate aminotransferase to platelet ratio index, fibrosis-4 score, and NAFLD fibrosis score. Between January 2017 and October 2017, 90 patients with NAFLD, who were followed up in the Department of Hepatology and Gastroenterology at the University of Campania “Luigi Vanvitelli,” were randomized into two groups: treatment group (silibinin plus vitamins D and E, n = 60) and untreated group (control group, n = 30) [180]. Their results showed that NAFLD patients in the treatment group had statistically significant improvements in metabolic markers, oxidative stress, endothelial dysfunction, and disease progression (p < 0.05) after 6-month treatment [180]. From January 2014 to June 2014, 62 patients with chronic HCV decompensated cirrhosis were randomized according to treatment plan at Cairo University Hospital: group A (n = 31) received 1,050 mg/day silymarin; group B (n = 31) received 420 mg/day silymarin [181]. From October 2016 to April 2017, Anushiravani et al. [182] conducted a randomized, double-blind, placebo-controlled trial of 150 consecutive NAFLD patients from an outpatient clinic in southern Iran: lifestyle plus placebo treatment (n = 30), metformin 500 mg/day (n = 30), silymarin 140 mg/day (n = 30), pioglitazone 15 mg/day (n = 30), and vitamin E 400 IU/day (n = 30) for 3 months. The results showed that after only 3 months, silymarin significantly improved liver transaminases, waist circumference, and BMI in NAFLD patients without any specific side effects [182]. In 2019, a trial tested a proprietary standardized formulation of silymarin (Legalon®, Rottapharm|Madaus, Mylan) at 5 medical centers in the United States [183]. Legalon® 420 mg, 700 mg treatment, or placebo given 3 times daily for 48 weeks. After 48 weeks, there were no significant differences in adverse events between treatment groups. After changing doses, the results were the same [183]. They considered a possible reason was that a large number of participants (49, 63%) did not meet histological entry criteria. Patients initially diagnosed with hepatitis C infection were collected from Bakhtawar Amin...
Medical College and Hospital in Multan, Pakistan, and randomized into two groups: the control group \( (n = 15) \) received direct-acting antivirals (DAA) alone (sofosbuvir and ribavirin; 400 mg/800 mg daily); the treatment group \( (n = 15) \) did not use DAA but received adjuvant therapy with silymarin (400 mg/day) and DAA (400/800 mg/day) over an 8-week period [184]. The results showed that adjuvant silymarin treatment increased the efficiency of DAA; decreased ALT, alkaline phosphatase (ALP), AST, and bilirubin levels \( (p > 0.05) \); improved superoxide dismutase (SOD) and total antioxidant status (TAS); reduced and oxidized glutathione (GSH and GSSG) and malondialdehyde (MDA) \( (p < 0.05) \); and reduced latent viral load, which suggests that silymarin may have a unique role in alleviating hepatitis C [184]. Since these clinical trials have demonstrated beneficial effects of silymarin in liver diseases such as NAFLD/NASH, it is gradually being registered as a drug for the treatment of liver diseases in many countries in Europe, Asia, America, Africa, and Australia. We then reviewed the possible mechanisms by which silymarin regulates NAFLD/NASH.

Silymarin increases the production of glutathione in the liver by increasing the availability of cysteine, its biosynthetic substrate, which in turn helps to enhance its antioxidant capacity in liver tissue [185]. The main mechanisms of silymarin in protecting liver cells are as follows: (1) It stabilizes membrane permeability by inhibiting lipid peroxidation and helps the liver maintain glutathione levels [185]. (2) Silymarin also blocks the activation of NF-κB by inhibiting the production of TNF-α, interferon-γ, IL-2, and IL-4, thereby preventing various effects of toxic chemicals such as carbon tetrachloride [186–188]. (3) It also inhibits the expression of TNF-α induced by α-amanita toxin of the poisonous mushroom [189]. Silymarin has a weak inhibitory effect on the formation of PGE2 in isolated rat Kupffer cells but has a strong inhibitory effect on the formation of LTB4, even at a low concentration (15 μmol/l) [190]. Selective inhibition of the latter explains the anti-inflammatory potential of silymarin in Kupffer cells. The anti-fibrotic effect of silymarin has been demonstrated in an animal model of alcohol-induced liver fibrosis in nonhuman primates treated with chronic alcohol [191]. Silymarin significantly reduces alcohol-induced increases in type I hepatic collagen [191]. Silibinin improves IR in a rat model of NAFLD by reducing visceral adiposity, enhancing lipolysis, and inhibiting gluconeogenesis [192]. Due to current lifestyle changes, both the frequency and amount of alcohol consumption are increasing, and silymarin may reduce lipid peroxidation and cell necrosis by enhancing cell viability [193]. Butorova et al. [194] treated patients with NAFLD or NASH with diet or silymarin for 2 months and showed that silymarin reduced or normalized parameters of liver function (transaminases levels) and improved ultrasound parameters of liver anatomy. Several recent randomized clinical studies have shown that silymarin significantly reduces the severity of steatosis, hepatic ballooning, and fibrosis compared with placebo, which may help improve liver conditions affected by NAFLD [195]. Compared with placebo, silymarin treatment reduces alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, which indicates that silymarin improves liver function [196,197]. In addition, in clinical trials in patients with liver cirrhosis, silymarin exerted antioxidant effects by inducing lipid peroxidation (as a free radical scavenger) and affecting enzyme systems associated with cellular damage leading to fibrosis and cirrhosis, which significantly reduce liver-related death [198]. Silymarin may also exert hepatoprotective effects by reducing oxidative stress and cytotoxicity. Silymarin, a Eurosil 85®-derived preparation, has great therapeutic potential and has been developed for the treatment of NAFLD and NASH [133, 179, 199]. Phase III clinical trials have confirmed that silymarin is the best drug for NAFLD patients at present, but its standardization, dosage form, and dosage regimen are difficult problems that need to be overcome now [195]. Taken together, these data suggest that silymarin treatment is effective in reducing fibrosis, liver stiffness, and metabolic markers (ALT, AST) levels; improving oxidative stress and endothelial dysfunction; and delaying disease progression in different regions. Silymarin is expected to be an effective emerging therapeutic drug for NAFLD and NASH.

7. Conclusions

In this review, the current signaling pathways in which hepatokines, stellakines, adipokines, myokines, and NF-κB are mutually regulated are discussed to explore their impact on inflammation, liver injury, and fibrosis in the progression of NAFLD. The review focuses on novel regulatory mechanisms and modes of action with known or suspected roles in regulating NAFLD and NASH metabolism (Figures 1–4).

Our study found that activation of NF-κB signaling pathway by hepatokines, stellakines, adipokines, and myokines aggravates liver injury and inflammation, promotes the progression of NAFLD to HCC, and regulates the proliferation, invasion, and metastasis of HCC. FGF21 knockdown promotes the progression of NASH to HCC through the TLR4/NF-κB/IL-17A axis. FGF21 down-regulates IκBα phosphorylation and NF-κB nuclear translocation to inhibit HSC activation, reducing the ratio of Bcl-2 to Bax to promote apoptosis to improve fibrosis. Elevation of NF-κB by HMGB1 accelerates the early liver injury and inflammatory response of NAFLD, promotes the progression of NAFLD to HCC, and regulates cell proliferation, invasion, and metastasis of HCC cell lines. Sitagliptin can protect the liver by directly inhibiting the proliferation of activated HSCs by promoting Nrf2 and inhibiting the NF-κB pathway, reducing the expression levels of inflammatory and pro-fibrotic factors. On the other hand, sitagliptin ameliorates NAFLD inflammation by reducing HMGB1-mediated TLR4/NF-κB signaling. However, TLR3/4 also mediates the NF-κB-CXCR4/7 pathway in the formation of Mallory–Denk bodies in human alcoholic hepatitis and NASH. p50 suppresses liver inflammation and immune response and alleviates liver injury by regulating HSC secretion of CCL2 and CXCL10. p65 ameliorates the inflammatory response by inhibiting HSC activation and reducing the secretion of stellakines. CTGF promotes the nuclear accumulation of p50 and p65 to protect the survival of primary HSCs, and CTGF can also transmit growth-promoting signals to HCC cells by...
activating nearby HSCs. Furthermore, NAMPT induces NF-κB and MKK3/6-p38 signaling to increase CCL20 in macrophages to promote fibrosis in HSCs. As a myokine, IL-6 is significantly associated with the increased risk of NAFLD and promotes HSC activation. p50 deficiency may promote IL-15 activation to stimulate NKT cell recruitment, which accelerates the progression of NASH to fibrosis.

Inhibiting the activation of NF-κB may represent a promising emerging class of NAFLD or NASH therapeutics. However, the therapeutic potential of hepatokines, adipokines, and myokines has not been effectively confirmed in clinical practice, so more research is needed to explore the mysteries among them. In the next step, we will carry out in vitro and in vivo experiments to explore the signaling pathway that inhibits NF-κB in regulating NAFLD, which will be beneficial to the development of new molecular treatments for NAFLD.

We should improve NAFLD education and awareness; manage NAFLD risk factors and comorbidities; establish appropriate screening, assessment, and diagnostic measures; and promptly refer to hepatologists when predisposition to NASH is identified. Furthermore, some emerging drugs such as silymarin have great therapeutic potential for NAFLD/NASH.

**Disclosure**

Xi Yang is the co-first author and main corresponding author.

**Conflicts of Interest**

The authors declare no conflicts of interest.

**Authors’ Contributions**

Yang B, Yang X, and Tan XM contributed equally to the literature review and manuscript draft; Fan W assisted in reviewing the literature and drafting the manuscript; Barbier-Torres L and Steggerda J did a critical reading of the manuscript; and Yang HP and Yang X provided critical editing and revision of the manuscript. All authors read and approved the final manuscript.

**Acknowledgments**

This work was supported by Medical and Health Appropriate Technology Development, Promotion and Application Project of Guangxi, S201664 and NIH (Grants R01CA172086 (HP Yang, JM Mato, and SC Lu) and P01CA233452 (HP Yang, E Seki, and SC Lu)).

**References**

[1] N. Chalasani, Z. Younossi, J. E. Lavine et al., “The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases,” *Hepatology*, vol. 67, no. 1, pp. 328–357, 2018.

[2] R. Loomba and A. J. Sanyal, “The global NAFLD epidemic,” *Nat Rev Gastroenterol Hepatol*, vol. 10, no. 11, pp. 686–690, 2013.

[3] P. L. Huang, “A comprehensive definition for metabolic syndrome,” *Disease Models & Mechanisms*, vol. 2, no. 5-6, pp. 231–237, 2009.

[4] Y. Li, L. Lu, J. Tu et al., “Reciprocal regulation between forskhead box M1/NAF-x and methionine adenosyltransferase 1A drives liver cancer,” *Hepatology*, vol. 72, no. 5, pp. 1682–1700, 2020.

[5] Y. M. Yang, S. Y. Kim, and E. Seki, “Inflammation and liver cancer: molecular mechanisms and therapeutic targets,” *Semin Liver Disease*, vol. 39, no. 01, pp. 026–042, 2019.

[6] M. Vucur, F. Reisinger, J. Gautheron et al., “RIP3 inhibits inflammatory hepatocarcinogenesis but promotes cholestasis by controlling caspase-8- and JNK-dependent compensatory cell proliferation,” *Cell Reports*, vol. 4, no. 4, pp. 776–790, 2013.

[7] J. M. Mato, C. Alonso, M. Noureddin, and S. C. Lu, “Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease,” *World Journal of Gastroenterology*, vol. 25, no. 24, pp. 3009–3020, 2019.

[8] T. Zeng, J. Zhou, L. He et al., “Blocking nuclear factor-kappa B protects against diet-induced hepatic steatosis and insulin resistance in mice,” *PLoS One*, vol. 11, no. 3, Article ID e0149677, 2016.

[9] A. Heida, N. Gruben, L. Catrysse et al., “The hepatocyte IKK- NF-κB axis promotes liver steatosis by stimulating de novo lipogenesis and cholesterol synthesis,” *Molecular Metabolism*, vol. 54, Article ID 101349, 2021.

[10] H. Häcker and M. Karin, “Regulation and function of IKK and IKK-related kinases,” *Sci STKE*, vol. 2006, no. 357, p. re13, 2006.

[11] I. Grattaglioiano, A. Di Ciala, J. Bai et al., “Protocols for mitochondria as the target of pharmacological therapy in the context of nonalcoholic fatty liver disease (NAFLD),” *Methods in Molecular Biology*, 2310, pp. 201–246, 2021.

[12] D. Cai, M. Yuan, D. F. Frantz et al., “Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB,” *Natural Medicine*, vol. 11, no. 2, pp. 183–190, 2005.

[13] S. Jiang and X. Chen, “HMGB1 siRNA can reduce damage to retinal cells induced by high glucose in vitro and in vivo,” *Drug Design, Development and Therapy*, vol. 11, pp. 783–795, 2017.

[14] Z. Gao, D. Hwang, F. Bataille et al., “Serine phosphorylation of insulin receptor substrate 1 by inhibitor kappa B kinase complex,” *Journal of Biological Chemistry*, vol. 277, no. 50, pp. 48115–48121, 2002.

[15] S. Bartesaghi, K. Wallenius, D. Hovdal et al., “Subcutaneous delivery of FGF21 mRNA therapy reverses obesity, insulin resistance, and hepatic steatosis in diet-induced obese mice,” *Molecular Therapy—Nucleic Acids*, vol. 28, pp. 500–513, 2022.

[16] H. Li, Q. Fang, F. Gao et al., “Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride,” *Journal of Hepatology*, vol. 53, no. 5, pp. 934–940, 2010.

[17] J. Díaz-Delfín, E. Hondares, R. Iglesias, M. Giralt, C. Caelles, and F. Villarroya, “TNF-α represses β-Klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway,” *Endocrinology*, vol. 153, no. 9, pp. 4238–4245, 2012.

[18] S. Smati, M. Régnier, T. Fougéray et al., “Regulation of hepatokine gene expression in response to fasting and feeding: influence of PPAR-α and insulin-dependent
signalling in hepatocytes,” *Diabetes & Metabolism*, vol. 46, no. 2, pp. 129–136, 2020.

19. P. Xu, Y. Zhang, Y. Liu et al., “Fibroblast growth factor 21 attenuates hepatic fibrogenesis through TGF-β1-smad2/3 and NF-κB signaling pathways,” *Toxicology and Applied Pharmacology*, vol. 290, pp. 43–53, 2016.

20. Q. Zheng, R. C. Martin, X. Shi et al., “Lack of FGF21 promotes NASH-HCC transition via hepatocyte-TLR4-IL-17A signaling,” *Theranostics*, vol. 10, no. 22, pp. 9923–9936, 2020.

21. L. Zhou, Q. Li, A. Chen et al., “KLF15-activating Twist2 ameliorated hepatic steatois by inhibiting inflammation and improving mitochondrial dysfunction via NF-κB-FGF21 or SREBP1c-FGF21 pathway,” *The FASEB Journal*, vol. 33, no. 12, pp. 14254–14269, 2019.

22. M. E. Shaker, “The contribution of sterile inflammation to the fatty liver disease and the potential therapies,” *Bio-medicine & Pharmacotherapy*, vol. 148, Article ID 112789, 2022.

23. B. Kambu, S. Yan, N. Huda, and X. M. Yin, “Role of high-mobility group box-1 in liver pathogenesis,” *International Journal of Molecular Sciences*, vol. 20, no. 21, p. 5314, 2019.

24. L. Li, L. Chen, L. Hu et al., “Nuclear factor high-mobility group box 1 mediating the activation of Toll-like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice,” *Hepatology*, vol. 54, no. 5, pp. 1620–1630, 2011.

25. M. Lin, J. Long, W. Li et al., “Hepatocyte high-mobility group box 1 protects against steatosis and cellular stress during high fat diet feeding,” *Molecular Medicine*, vol. 26, no. 1, p. 115, 2020.

26. W. Zeng, W. Shan, L. Gao et al., “Inhibition of HMGB1 release via salvinanolic acid B-mediated SIRT1 up-regulation protects rats against non-alcoholic fatty liver disease,” *Scientific Reports*, vol. 5, no. 1, Article ID 16013, 2015.

27. W. J. Liang, H. W. Yang, H. N. Liu, W. Qian, and X. L. Chen, “HMGB1 upregulates NF-κB by inhibiting IκB-α and associates with diabetic retinopathy,” *Life Sciences*, vol. 241, Article ID 117146, 2020.

28. Y. Chen, C. Lin, Y. Liu, and Y. Jiang, “HMGB1 promotes HCC progression partly by downregulating p21 via ERK/c-Myc pathway and upregulating MMP-2,” *Tumor Biology*, vol. 37, no. 4, pp. 4399–4408, 2016.

29. R. C. Chen, P. P. Yi, R. R. Zhou et al., “The role of HMGB1-RAGE axis in migration and invasion of hepatocellular carcinoma cell lines,” *Molecular and Cellular Biochemistry*, vol. 390, no. 1-2, pp. 271–280, 2014.

30. R. Afin, S. Arumugam, A. Rahman et al., “Curcumin ameliorates liver damage and progression of NASH in NASH-HCC mouse model possibly by modulating HMGB1-NF-κB translocation,” *International Immunopharmacology*, vol. 44, pp. 174–182, 2017.

31. M. M. Allam, R. M. Ibrahim, W. B. El Gazzar, and M. A. Said, “Dipeptidyl peptidase-4 (DPP-4) inhibitor downregulates HMGB1/TLR4/NF-κB signaling pathway in a diabetic rat model of non-alcoholic fatty liver disease,” *Archives of Physiology and Biochemistry*, pp. 1–9, 2021.

32. J. M. Henderson, M. S. W. Xiang, J. C. Huang et al., “Dipeptidyl peptidase inhibition enhances CD8 T cell recruitment and activates intrahepatic inflammation in a murine model of hepatocellular carcinoma,” *Cancers (Basel)*, vol. 13, no. 21, p. 5495, 2021.

33. M. Sagara, T. Iijima, M. Kase et al., “Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis,” *Journal of Diabetes and Its Complications*, vol. 35, no. 5, Article ID 107885, 2021.

34. C. Baumeier, L. Schlüter, S. Saussenthaler et al., “Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease,” *Molecular Metabolism*, vol. 6, no. 10, pp. 1254–1263, 2017.

35. H. Yang, N. Magilnick, C. Lee et al., “Nrf1 and Nrf2 regulate rat glutamate-cysteine ligase catalytic subunit transcription indirectly via NF-κB and AP-1,” *Molecular and Cellular Biology*, vol. 25, no. 14, pp. 5933–5946, 2005.

36. M. H. Sharawy, D. H. El-Kashef, A. A. Shaaban, and D. S. El-Agamy, “Anti-fibrotic activity of sitaglitin against concanavalin A-induced hepatic fibrosis. Role of Nrf2 activation/NF-κB inhibition,” *International Immunopharmacology*, vol. 100, Article ID 108088, 2021.

37. H. Zhang, D. Sun, G. Wang et al., “Alogliptin alleviates liver fibrosis via suppression of activated hepatic stellate cell,” *Biochemical and Biophysical Research Communications*, vol. 511, no. 2, pp. 387–393, 2019.

38. S. A. Lee, J. J. Yuen, H. Jiang, B. B. Kahn, and W. S. Blaner, “Adipocyte-specific overexpression of retinol-binding protein 4 causes hepatic steatosis in mice,” *Hepatology*, vol. 64, no. 5, pp. 1534–1546, 2016.

39. X. Wang, X. Chen, H. Zhang et al., “Circulating retinol-binding protein 4 is associated with the development and regression of non-alcoholic fatty liver disease,” *Diabetes & Metabolism*, vol. 46, no. 2, pp. 119–128, 2020.

40. K. M. Farjo, R. A. Farjo, S. Halsey, G. Moiseyev, and J. X. Ma, “Retinol-binding protein 4 induces inflammation in human endothelial cells by an NADPH oxidase- and nuclear factor kappa B-dependent and retinol-independent mechanism,” *Molecular and Cellular Biology*, vol. 32, no. 24, pp. 5103–5115, 2012.

41. J. Norseen, T. Hosooka, A. Hammarstedt et al., “Retinol-binding protein 4 inhibits insulin signaling in adipocytes by inducing proinflammatory cytokines in macrophages through a c-Jun N-terminal kinase- and Toll-like receptor 4-dependent and retinol-independent mechanism,” *Molecular and Cellular Biology*, vol. 32, no. 10, pp. 2010–2019, 2012.

42. Z. B. Deng, A. Poliakov, R. W. Hardy et al., “Adipose tissue exosome-like vesicles mediate activation of macrophage-induced insulin resistance,” *Diabetes*, vol. 58, no. 11, pp. 2498–2505, 2009.

43. L. Shi, J. Resaul, S. Owen, L. Ye, and W. G. Jiang, “Clinical and therapeutic implications of follistatin in solid tumours,” *Cancer Genomics & Proteomics*, vol. 13, no. 6, pp. 425–436, 2016.

44. O. K. Parfenova, V. G. Kukes, and D. V. Grishin, “Follistatin-like proteins: structure, functions and biomedical importance,” *Biomedicines*, vol. 9, no. 8, p. 999, 2021.

45. Y. Liu, J. Wei, Y. Zhao et al., “Follistatin-like protein 1 promotes inflammatory reactions in nucleus pulposus cells by interacting with the MAPK and NFκB signaling pathways,” *Oncotarget*, vol. 8, no. 26, pp. 43023–43034, 2017.

46. L. Chen and Z. Liu, “Downregulation of FSTL1 attenuates the inflammation injury during Streptococcus pneumoniae infection by inhibiting the NLRP3 and TLR4-NFκB signaling pathway,” *Molecular Medicine Reports*, vol. 20, no. 6, pp. 5345–5352, 2019.

47. P. F. Hu, C. Y. Ma, F. F. Sun, W. P. Chen, and L. D. Wu, “Follistatin-like protein 1 (FSTL1) promotes chondrocyte expression of matrix metalloproteinase and inflammatory arthritis,” *Arthritis & Research & Therapy*, vol. 13, no. 2, pp. 129–136, 2020.
factors via the NF-κB pathway,” *Journal of Cellular and Molecular Medicine*, vol. 23, no. 3, pp. 2230–2237, 2019.

[48] L. Bartholin, S. Guindon, S. Martel, L. Corbo, and R. Rimokh, “Identification of NF-kappaB responsive elements in folli-statin related gene (FLRG) promoter,” *Gene*, vol. 393, no. 1-2, pp. 153–162, 2007.

[49] A. Yndestad, J. W. Haukeland, T. B. Dahl et al., “A complex role of activin A in non-alcoholic fatty liver disease,” *Am J Gastroenterol*, vol. 104, no. 9, pp. 2196–2205, 2009.

[50] C. Wu, Y. Borné, R. Gao et al., “Elevated circulating folli-statin associates with an increased risk of type 2 diabetes,” *Nature Communications*, vol. 12, no. 1, p. 6486, 2021.

[51] X. Wang, J. Xie, J. Pang et al., “Serum SHBG is associated with the development and regression of nonalcoholic fatty liver disease: a prospective study,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 105, no. 3, pp. e791–e804, 2020.

[52] A. Peter, K. Kantartzis, J. Machann et al., “Relationships of circulating sex hormone-binding globulin with metabolic traits in humans,” *Diabetes*, vol. 59, no. 12, pp. 3167–3173, 2010.

[53] R. Simó, A. Barbosa-Desongles, C. Sáez-Lopez, A. Lecube, C. Hernandez, and D. M. Selva, “Molecular mechanism of tnfα-induced down-regulation of SHBG expression,” *Molecular Endocrinology*, vol. 26, no. 3, pp. 438–446, 2012.

[54] X. Qu and R. Donnelly, “Sex hormone-binding globulin (SHBG) as an early biomarker and therapeutic target in polycystic ovary syndrome,” *International Journal of Molecular Sciences*, vol. 21, no. 21, p. 8191, 2020.

[55] X. Hua, M. Li, F. Pan, Y. Xiao, W. Cui, and Y. Hu, “Non-alcoholic fatty liver disease is an influencing factor for the association of SHBG with metabolic syndrome in diabetes patients,” *Scientific Reports*, vol. 7, no. 1, Article ID 14532, 2017.

[56] S. R. Lee, Y. H. Lee, H. Yang et al., “Sex hormone-binding globulin suppresses NAFLD-triggered hepatocarcinogenesis after menopause,” *Carcinogenesis*, vol. 40, no. 8, pp. 1031–1041, 2019.

[57] M. A. Icer and H. Yıldırım, “Effects of fetuin-A with diverse functions and multiple mechanisms on human health,” *Clinical Biochemistry*, vol. 88, pp. 1–10, 2021.

[58] P. G. Yamasandhi, M. Dharmaningam, and A. Balekuduru, “Fetuin-A in newly detected type 2 diabetes mellitus as a marker of non-alcoholic fatty liver disease,” *Indian Journal of Gastroenterology*, vol. 40, no. 6, pp. 556–562, 2021.

[59] D. Chattopadhyay, S. Das, S. Guria, S. Basu, and S. Mukherjee, “Fetuin-A regulates adipose tissue macrophage content and activation in insulin resistant mice through MCP-1 and iNOS: involvement of IFNγ-JAK2-STAT1 pathway,” *Biochemical Journal*, vol. 478, no. 22, pp. 4027–4043, 2021.

[60] S. T. Mathews, N. Chellam, P. R. Srinivas et al., “IL2-HSG, a specific inhibitor of insulin receptor autophosphorylation, interacts with the insulin receptor,” *Molecular and Cellular Endocrinology*, vol. 164, no. 1-2, pp. 87–98, 2000.

[61] D. Pal, S. Dasgupta, R. Kundu et al., “Fetuin-A acts as an endogenous ligand ofTLR4 to promote lipid-induced insulin resistance,” *Natural Medicine*, vol. 18, no. 8, pp. 1279–1285, 2012.

[62] M. Mularczyk, Y. Bourerba, A. Kowalczyk, K. Marycz, and L. Bourerba, “Probiotics-rich emulsion improves insulin signalling in Palmitate/Oleate-challenged human hepato-carcinoma cells through the modulation of Fetuin-A/TLR4-JNK-NF-κB pathway,” *Biomedicine & Pharmacotherapy*, vol. 139, Article ID 111560, 2021.

[63] S. Dasgupta, S. Bhattacharya, A. Biswas et al., “NF-κB mediates lipid-induced fetuin-A expression in hepatocytes that impairs adipocyte function effecting insulin resistance,” *Biochemical Journal*, vol. 429, no. 3, pp. 451–462, 2010.

[64] J. Wang, Y. Chen, R. Pan et al., “Leukocyte cell-derived chemotaxin 2 promotes the development of nonalcoholic fatty liver disease through STAT-1 pathway in mice,” *Liver International*, vol. 41, no. 4, pp. 777–787, 2021.

[65] N. Takata, K. A. Ishii, H. Takayama et al., “LECT2 as a hepatokine links liver steatosis to inflammation via activating tissue macrophages in NASH,” *Scientific Reports*, vol. 11, no. 1, p. 555, 2021.

[66] H. X. Shen, L. Li, Q. Chen et al., “LECT2 association with macrophage-mediated killing of Helicobacter pylori by activating NF-κB and nitric oxide production,” *Genetics and Molecular Research*, vol. 15, no. 4, 2016.

[67] T. W. Jung, Y. H. Chung, H. C. Kim, A. M. Abd El-Aty, and J. H. Jeong, “LECT2 promotes inflammation and insulin resistance in adipocytes via P38 pathways,” *Journal of Molecular Endocrinology*, vol. 61, no. 1, pp. 37–45, 2018.

[68] L. Shojaei, A. Iorga, and L. Dara, “Cell death in liver diseases: a review,” *International Journal of Molecular Sciences*, vol. 21, no. 24, p. 9682, 2020.

[69] X. Xiong, H. Kuang, S. Ansari et al., “Landscape of intercellular crosstalk in healthy and NASH liver revealed by single-cell secretome gene analysis,” *Molecular Cell*, vol. 75, no. 3, pp. 644–660, 2019.

[70] E. J. Chang, S. K. Lee, Y. S. Song et al., “IL-34 is associated with obesity, chronic inflammation, and insulin resistance,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 99, no. 7, pp. E1263–E1271, 2014.

[71] R. Mohallem and U. K. Aryal, “Regulators of TNFα mediated insulin resistance elucidated by quantitative proteomics,” *Scientific Reports*, vol. 10, no. 1, Article ID 20878, 2020.

[72] S. C. Sun, “The non-canonical NF-κB pathway in immunity and inflammation,” *Nature Reviews Immunology*, vol. 17, no. 9, pp. 545–558, 2017.

[73] J. Jin, H. Hu, H. S. Li et al., “Noncanonical NF-κB pathway controls the production of type I interferons in antiviral innate immunity,” *Immunity*, vol. 40, no. 3, pp. 342–354, 2014.

[74] T. Konishi, R. M. Schuster, H. S. Goetzman, C. C. Caldwell, and A. B. Lentsch, “Fibrotic liver has prompt recovery after ischemia-reperfusion injury,” *American Journal of Physiology-Gastrointestinal and Liver Physiology*, vol. 318, no. 1, pp. G390–g400, 2020.

[75] L. Hong, D. Shejiao, C. Fenrong, Z. Gang, and D. Lei, “Regulators of TNFα in NASH and changes of its pathways,” *Journal of Cellular and Molecular Medicine*, vol. 25, no. 2, pp. 212–223, 2021.
monocyte-like cell line by MAPK- and NF-κB-dependent mechanisms; the modulating effect of insulin,” *Cell and Tissue Research*, vol. 343, no. 2, pp. 379–387, 2011.

[108] S. M. Reilly and A. R. Saltiel, “Adapting to obesity with adipose inflammation,” *Nature Reviews Endocrinology*, vol. 13, no. 11, pp. 633–643, 2017.

[109] A. Nani, B. Murtaza, A. Sayed Khan, N. A. Khan, and A. Hichami, “Antioxidant and anti-inflammatory potential of polyphenols contained in Mediterranean diet in obesity: molecular mechanisms,” *Molecules*, vol. 26, no. 4, p. 985, 2021.

[110] D. Kumar, B. Lee, K. J. Puan et al., “Resistin expression in human monocytes is controlled by two linked promoter SNPs mediating NFKB p50/p50 binding and C-methylation,” *Scientific Reports*, vol. 9, no. 1, Article ID 15245, 2019.

[111] G. Fantuzzi, “Adipose tissue, adipokines, and inflammation,” *Journal of Allergy and Clinical Immunology*, vol. 115, no. 5, pp. 911–919, 2005.

[112] P. Codoñer-Franch and E. Alonso-Iglesias, “Resistin: insulin resistance to malignancy,” *Clinica Chimica Acta*, vol. 438, pp. 46–54, 2015.

[113] Y. Y. Hsieh, C. H. Shen, W. S. Huang et al., “Resistin-induced stromal cell-derived factor-1 expression through Toll-like receptor 4 and activation of p38 MAPK/ NFκB signaling pathway in gastric cancer cells,” *Journal of Biomedical Science*, vol. 21, no. 1, p. 59, 2014.

[114] S. Chelteschi, I. Gallo, M. Barbarino et al., “MicroRNA mediates visfatin and resistin induction of oxidative stress in human osteoarthritic synovial fibroblasts via NF-κB pathway,” *International Journal of Molecular Sciences*, vol. 20, no. 20, p. 5200, 2019.

[115] M. F. O’Leary, G. R. Wallace, E. T. Davis et al., “Obese subcutaneous adipose tissue impairs human myogenesis, particularly in old skeletal muscle, via resistin-mediated activation of NFκB,” *Scientific Reports*, vol. 8, no. 1, Article ID 15360, 2018.

[116] F. Wen, Y. Yang, D. Jin, J. Sun, X. Yu, and Z. Yang, “miRNA-145 is involved in the development of resistin-induced insulin resistance in HepG2 cells,” *Biochemical and Biophysical Research Communications*, vol. 445, no. 2, pp. 517–523, 2014.

[117] C. Bertolini, P. Sancho-Bru, P. Failli et al., “Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells,” *The American Journal of Pathology*, vol. 169, no. 6, pp. 2042–2053, 2006.

[118] N. Arslan, Y. Tokgoz, T. Kume et al., “Evaluation of serum neopterin levels and its relationship with adipokines in pediatric obesity-related nonalcoholic fatty liver disease and healthy adolescents,” *Journal of Pediatric Endocrinology & Metabolism (JPEM)*, vol. 26, no. 11–12, pp. 1141–1147, 2013.

[119] C. Berger and N. Klötting, “Leptin, receptor compound heterozygosity in humans and animal models,” *International Journal of Molecular Sciences*, vol. 22, no. 9, p. 4475, 2021.

[120] K. Vuolteenaho, A. Koskinen, M. Kukkanen et al., “Leptin enhances synthesis of proinflammatory mediators in human osteoarthritic cartilage—mediator role of NO in leptin-InducedPGE2, IL-6, and IL-8 production,” *Mediators of Inflammation*, vol. 2009, Article ID 345838, 10 pages, 2009.

[121] S. Chen, Q. Wang, B. Han et al., “Effects of leptin-modified human placenta-derived mesenchymal stem cells on angiogenic potential and peripheral inflammation of human umbilical vein endothelial cells (HUVECs) after X-ray radiation,” *Journal of Zhejiang University Science B*, vol. 21, no. 4, pp. 327–340, 2020.

[122] G. Faustmann, B. Tiran, T. Maimari et al., “Circulating leptin and NF-κB activation in peripheral blood mononuclear cells across the menstrual cycle,” *Biofactors*, vol. 42, no. 4, pp. 376–387, 2016.

[123] L. A. O’Reilly, T. L. Putoczki, L. A. Mielke et al., “Loss of NF-κB causes gastric cancer with aberrant inflammation and expression of immune checkpoint regulators in a STAT-1-dependent manner,” *Immunity*, vol. 48, no. 3, pp. 570–583, 2018.

[124] L. Ye, G. Jia, Y. Li et al., “C1q/TNF-related protein 4 restores leptin sensitivity by downregulating NF-κB signaling and microglial activation,” *Journal of Neuroinflammation*, vol. 18, no. 1, p. 159, 2021.

[125] L. Zhong, J. Jia, and G. Ye, “Rian/miR-210-3p/NFκB feedback loop promotes hypoxia-induced cell apoptosis in myocardial infarction through deactivating the PI3K/akt signaling pathway,” *Journal of Cardiovascular Pharmacology*, vol. 76, no. 2, pp. 207–215, 2020.

[126] Q. Zhang, J. Wang, F. Huang, Y. Yao, and L. Xu, “Leptin induces NAFLD progression through infiltrated CD8+ T lymphocytes mediating pyroptotic-like cell death of hepatocytes and macrophages,” *Digestive and Liver Disease*, vol. 53, no. 5, pp. 598–605, 2021.

[127] R. Ye and P. E. Scherer, “Adiponectin, driver or passenger on the road to insulin sensitivity?” *Molecular Metabolism*, vol. 2, no. 3, pp. 133–141, 2013.

[128] H. Fang and R. L. Judd, “Adiponectin regulation and function,” *Comprehensive Physiology*, vol. 8, no. 3, pp. 1031–1063, 2018.

[129] F. Haugen and C. A. Drevon, “Activation of nuclear factor-κB by high molecular weight and globular adiponectin,” *Endocrinology*, vol. 148, no. 11, pp. 5478–5486, 2007.

[130] M. Jian, J. S. C. Kwan, M. Bunting, R. C. L. Ng, and K. H. Chan, “Adiponectin suppresses amyloid-β oligomer (AβO)-induced inflammatory response of microglia via AdipoR1-AMPK-NF-κB signaling pathway,” *Journal of Neuroinflammation*, vol. 16, no. 1, p. 110, 2019.

[131] A. Salminen, J. M. T. Hyttinen, and K. Kaarniranta, “AMP-activated protein kinase inhibits NF-κB signaling and inflammation: impact on healthspan and lifespan,” *Journal of Molecular Medicine (Berl)*, vol. 89, no. 7, pp. 667–676, 2011.

[132] W. Yang, W. Yuan, X. Peng et al., “PPAR γ/innat/NF-κB Axis involved in promoting effects of adiponectin on preadipocyte differentiation,” *Mediators of Inflammation*, vol. 2019, Article ID 5618023, 9 pages, 2019.

[133] M. Abou-Samra, R. Boursereau, S. Lecompte, L. Noel, and A. Polyzos, K. A. Toulis, D. G. Goulis, C. Zavos, and J. Kountouras, “Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis,” *The American Journal of Pathology*, vol. 167, no. 7, pp. 2077–2085, 2017.

[134] S. A. Polyzos, K. A. Toulis, D. G. Goulis, C. Zavos, and J. Kountouras, “Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis,” *Metabolism*, vol. 60, no. 3, pp. 313–326, 2011.

[135] A. S. Ralphs, J. Stehr, E. Gokara, and W. Kiess, “Physiological and pathophysiological roles of NAMPT and NAD metabolism,” *Nature Reviews Endocrinology*, vol. 11, no. 9, pp. 535–546, 2015.

[136] Y. Chen, M. Chen, Z. Wu, and S. Zhao, “Ox-LDL induces ER stress and promotes the adipokines secretion in 3T3-L1 adipocytes,” *PLoS One*, vol. 8, no. 10, Article ID e81379, 2013.

[137] H. S. Kim, S. Y. Han, H. Y. Sung et al., “Blockade of visfatin induction by oleic acid via disturbing IL-6-TRAF6-NFκB signaling of adipocytes,” *Experimental Biology and Medicine (Maywood)*, vol. 239, no. 3, pp. 284–292, 2014.
[138] S. R. Kim, S. K. Bae, K. S. Choi et al., “Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2,” *Biochemical and Biophysical Research Communications*, vol. 357, no. 1, pp. 150–156, 2007.

[139] T. Romacho, V. Azcutia, M. Vázquez-Bella et al., “Extra-cellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity,” *Diabetologia*, vol. 52, no. 11, pp. 2455–2463, 2009.

[140] A. R. Moscoso, R. R. Gerner, and H. Tilg, “Pre-B cell colony enhancing factor/NAMPT/visfatin in inflammation and obesity-related disorders,” *Current Pharmaceutical Design*, vol. 16, no. 17, pp. 1913–1920, 2010.

[141] T. B. Dahl, J. W. Haukeland, A. Yndestad et al., “Intracellular nicotinamide phosphoribosyltransferase activity is down-regulated in nonalcoholic fatty liver disease,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 95, no. 6, pp. 3039–3047, 2010.

[142] Y. J. Heo, S. E. Choi, J. Y. Jeon et al., “Visfatin induces inflammation and insulin resistance via the NF-xB and STAT3 signaling pathways in hepatocytes,” *Journal of Diabetes Research*, vol. 2019, Article ID 4021623, 11 pages, 2019.

[143] Y. J. Heo, S. E. Choi, N. Lee et al., “CCL20 induced by visfatin in macrophages via the NF-xB and MKK3/6-p38 signaling pathways contributes to hepatic stellate cell activation,” *Molecular Biology Reports*, vol. 47, no. 6, pp. 4285–4293, 2020.

[144] J. Eckel, “Myokines in metabolic homeostasis and diabetes,” *Diabetologia*, vol. 62, no. 9, pp. 1523–1528, 2019.

[145] B. K. Pedersen, “Physical activity and muscle-brain cross-talk,” *Nature Reviews Endocrinology*, vol. 15, no. 7, pp. 383–392, 2019.

[146] B. K. Pedersen and M. A. Febbraio, “Muscles, exercise and obesity: skeletal muscle as a secretory organ,” *Nature Reviews Endocrinology*, vol. 8, no. 8, pp. 457–465, 2012.

[147] F. B. Benatti and B. K. Pedersen, “Exercise as an anti-inflammatory therapy for rheumatic diseases-myokine regulation,” *Nature Reviews Rheumatology*, vol. 11, no. 2, pp. 86–97, 2015.

[148] T. M. Kistner, B. K. Pedersen, and D. E. Lieberman, “Interleukin 6 as an energy allocator in muscle tissue,” *Nature Metabolism*, vol. 4, no. 2, pp. 170–179, 2022.

[149] L. Lang Lehrskov, M. P. Lyngbaek, L. Soederlund et al., “Interleukin-6 delays gastric emptying in humans with direct effects on glycemic control,” *Cell Metabolism*, vol. 27, no. 6, pp. 1201–1211, 2018.

[150] X. Hou, S. Yin, R. Ren et al., “Myeloid-cell-specific IL-6 signaling promotes MicroRNA-223-enriched exosome production to attenuate NAFLD-associated fibrosis,” *Hepatology*, vol. 74, no. 1, pp. 116–132, 2021.

[151] D. Skuratovskaia, A. Komar, M. Vulf et al., “IL-6 reduces mitochondrial replication, and IL-6 receptors reduce chronic inflammation in NAFLD and type 2 diabetes,” *International Journal of Molecular Sciences*, vol. 22, no. 4, p. 1774, 2021.

[152] H. Tutunchi, A. Ostadrhami, M. Saghaei-Asl et al., “Expression of NF-xB, IL-6, and IL-10 genes, body composition, and hepatic fibrosis in obese patients with NAFLD-Combined effects of oleanoylaminoleate supplementation and calorie restriction: a triple-blind randomized controlled clinical trial,” *Journal of Cellular Physiology*, vol. 236, no. 1, pp. 417–426, 2021.

[153] N. Anderson and J. Borlak, “Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis,” *Pharmacological Reviews*, vol. 60, no. 3, pp. 311–357, 2008.

[154] S. Joshi-Barve, S. S. Barve, K. Amancherla et al., “Palmitic acid induces production of proinflammatory cytokine interleukin-8 from hepatocytes,” *Hepatology*, vol. 46, no. 3, pp. 823–830, 2007.

[155] K. H. Hsu, C. W. Wei, Y. R. Su et al., “Upregulation of RelB in the miR-122 knockout mice contributes to increased levels of proinflammatory chemokines/cytokines in the liver and macrophages,” *Immunochemistry Letters*, vol. 226, pp. 22–30, 2020.

[156] T. Zhu, J. Chen, Y. Zhao et al., “Neuromedin B mediates IL-6 and COX-2 expression through NF-xB/P65 and AP-1/C-JUN activation in human primary myometrial cells,” *Biochemistry Reports*, vol. 39, no. 10, Article ID BSR20192319, 2019.

[157] X. Wang, H. Wu, Q. Zhang et al., “NFKB2 inhibits NGFR1 transcription to affect nucleus pulposus cell degeneration and inflammation in intervertebral disc degeneration/fibromatosis,” *Mechanisms of Ageing and Development*, vol. 197, Article ID 111511, 2021.

[158] J. Y. Huh, “The role of exercise-induced myokines in regulating metabolism,” *Archives of Pharmacal Research*, vol. 41, no. 1, pp. 14–29, 2018.

[159] Y. Duan, F. Li, W. Wang et al., “Interleukin-15 in obesity and metabolic dysfunction: current understanding and future perspectives,” *Obesity Reviews*, vol. 18, no. 10, pp. 1147–1158, 2017.

[160] J. L. Reyes, D. T. Vaman, T. Vo et al., “Neutralization of IL-15 abrogates experimental immune-mediated cholangitis in diet-induced obese mice,” *Scientific Reports*, vol. 8, no. 1, p. 3127, 2018.

[161] Y. Koda, T. Teratani, P. S. Chu et al., “CD8(+)-tissue-resident memory T cells promote liver fibrosis resolution by inducing apoptosis of hepatic stellate cells,” *Nat Commun*, vol. 12, no. 1, p. 4474, 2021.

[162] Y. Cepero-Donates, G. Lacraz, F. Ghbobdi et al., “Interleukin-15-mediated inflammation promotes non-alcoholic fatty liver disease,” *Cytokine*, vol. 82, pp. 102–111, 2016.

[163] K. P. Stone, A. J. Kastin, and W. Pan, “NFKB is an unexpected major mediator of interleukin-15 signaling in cerebral endothelia,” *Cellular Physiology and Biochemistry*, vol. 28, no. 1, pp. 115–124, 2011.

[164] L. Locatelli, S. Sutti, M. Vacchiano, C. Bozzola, and E. Albano, “NF-xB1 deficiency stimulates the progression of non-alcoholic steatohepatitis (NASH) in mice by promoting NKT-cell-mediated responses,” *Clinical Science*, vol. 124, no. 4, pp. 279–287, 2013.

[165] D. Xu, D. Lian, Z. Zhang, Y. Liu, J. Sun, and L. Li, “Brain-derived neurotrophic factor is regulated via MyD88/NF-xB signaling in experimental Streptococcus pneumoniae meningitis,” *Scientific Reports*, vol. 7, no. 1, p. 3545, 2017.

[166] M. C. Lu, I. T. Lee, L. Z. Hong et al., “Coffeebean activates the CaMKII/CREB/BDNF pathway, normalizes autophagy and apoptosis signaling in nonalcoholic fatty liver rodent model,” *Nutrients*, vol. 13, no. 10, p. 3652, 2021.

[167] Y. Hattori, H. Yamada, E. Munetsuna et al., “Increased brain-derived neurotrophic factor in the serum of persons with nonalcoholic fatty liver disease,” *Endocrine Journal*, vol. 69, no. 8, 2022.

[168] F. M. Sanai, F. Abaalkhail, F. Hasan, M. H. Faroqui, N. A. Nahdi, and Z. M. Younossi, “Management of non-alcoholic fatty liver disease in the Middle East,” *World Journal of Gastroenterology*, vol. 26, no. 25, pp. 3528–3541, 2020.

[169] V. W. S. Wong, W. K. Chan, S. Chitturi et al., “Asia-pacific working party on non-alcoholic fatty liver disease guidelines 2017-Part 1: definition, risk factors and assessment,” *Journal of Gastroenterology and Hepatology*, vol. 33, no. 1, pp. 70–85, 2018.
European Association for the Study of the Liver EASL, European Association for the Study of Diabetes EASD, and European Association for the Study of Obesity EASO, “EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease,” *Obes Facts*, vol. 9, no. 2, pp. 65–90, 2016.

B. A. Neuschwander-Tetri, "Non-alcoholic fatty liver disease," *BMC Medicine*, vol. 15, no. 1, p. 45, 2017.

E. Tsai and T. P. Lee, "Diagnosis and evaluation of non-alcoholic fatty liver disease/nonalcoholic steatohepatitis, including noninvasive biomarkers and transient elastography," *Clinics in Liver Disease*, vol. 22, no. 1, pp. 73–92, 2018.

M. Alexander, A. K. Loomis, J. Fairburn-Beech et al., "Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease," *BMC Medicine*, vol. 16, no. 1, p. 130, 2018.

L. Abenavoli, A. A. Izzo, N. Milić, C. Cicala, A. Santini, and E. Tsai and T. P. Lee, “Diagnosis and evaluation of non-alcoholic fatty liver disease/nonalcoholic steatohepatitis, including noninvasive biomarkers and transient elastography,” *Clinics in Liver Disease*, vol. 22, no. 1, pp. 73–92, 2018.

M. Alexander, A. K. Loomis, J. Fairburn-Beech et al., “Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease,” *BMC Medicine*, vol. 16, no. 1, p. 130, 2018.

L. Abenavoli, A. A. Izzo, N. Milić, C. Cicala, A. Santini, and R. Capasso, "Milk thistle (Silybum marianum): a concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases," *Phytotherapy Research*, vol. 32, no. 11, pp. 2202–2213, 2018.

G. Hahn, H. D. Lehmann, M. Kürten, H. Uebel, and G. Vogel, "On the pharmacology and toxicology of silymarin, an antihepatotoxic active principle from Silybum marianum (L.) Gaertn," *Arzneimittelforschung*, vol. 18, no. 6, pp. 698–704, 1968.

S. Javed, K. Kohli, and M. Ali, "Reassessing bioavailability of silymarin," *Alternative Medicine Review*, vol. 16, no. 3, pp. 239–249, 2011.

A. Gillessen and H. H. J. Schmidt, "Silymarin as supportive treatment in liver diseases: a narrative review," *Advances in Therapy*, vol. 37, no. 4, pp. 1279–1301, 2020.

C. Mulrow, V. Lawrence, B. Jacobs et al., "Milk thistle: effects on liver disease and cirrhosis and clinical adverse effects," *Evid Rep Technol Assess (Summ)*, no. 21, pp. 1–3, 2000.

C. Wah Kheong, N. R. Nik Mustapha, and S. Mahadeva, "A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis," *Clinical Gastroenterology and Hepatology*, vol. 15, no. 12, pp. 1940–1949, 2017.

A. Federico, M. Dallio, M. Masarone et al., "Evaluation of the effect derived from silybin with vitamin D and vitamin E administration on clinical, metabolic, endotheilial dysfunction, oxidative stress parameters, and serological worsening markers in nonalcoholic fatty liver disease patients," *Oxidative Medicine and Cellular Longevity*, vol. 2019, Article ID 8742075, 12 pages, 2019.

W. F. Fathalah, M. A. Abdel Aziz, N. H. Abou El Soud, and M. E. S. El Raziky, "High dose of silymarin in patients with decompensated liver disease: a randomized controlled trial," *Journal of Interferon & Cytokine Research*, vol. 37, no. 11, pp. 480–487, 2017.

A. Anushiravani, N. Haddadi, M. Pourfarmanbar, and V. Mohammadkarimi, "Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial," *European Journal of Gastroenterology & Hepatology*, vol. 31, no. 5, pp. 613–617, 2019.

V. J. Navarro, S. H. Belle, M. D’Amato et al., "On behalf of the Silymarin in NASHiC and Hepatitis SynCH Study Group. Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: a randomized, double-blind, placebo controlled trial," *PLoS One*, vol. 14, no. 9, Article ID e0221683, 2019.

S. Ahmed, N. Ullah, S. Parveen et al., "Effect of silymarin as an adjunct therapy in combination with sofosbuvir and ribavirin in hepatitis C patients: a miniature clinical trial," *Oxidative Medicine and Cellular Longevity*, vol. 2022, Article ID 9199190, 14 pages, 2022.